Learn more about groundbreaking Simoa technology!
With much enthusiasm following the research coming out of AD/PD™2021, we are pleased to bring together leading industry experts to discuss neurological advancements related to the ultra-sensitive quantification of pTau181, pTau217, pTau231, and other neurological biomarkers. This panel discussion and live Q and A will cover the latest developments and opportunities to impact AD clinical trials and diagnostics.
The discussion will be led by Quanterix Chairman, Chief Executive Officer, and President, Kevin Hrusovsky and will feature Charlotte Teunissen, Ph.D., UMC Amsterdam, and Henrik Zetterberg. Ph.D., University of Gothenberg.